Under construction – not a live service
Sign in
Taking people in FranceNo phase

Following immune changes and health over 15 years in people with HIV

Follows immune system changes and health problems in adults living with HIV.

Plain-language title generated from the registry record
Registry title: Evolution of the Clinical, Immuno-virological and Aging Trajectory of Patients Living With HIV

Key facts

Where
Paris, FranceSee the site

Where in France

  • Hopital Pitie-SalpetriereParis, FranceTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
Trial code
NCT06258122
Record updated
10 January 2025
Original description
Main objective is:Read full original descriptionShow less

Evolution Over 15 Years (2008-2023) of the Clinical, Immuno-virological and Aging Trajectory of Patients Living With HIV

Main objective is:

* To characterize the evolution of the immuno-virological profile of circulating blood cells and immune aging in patients who had participated to TEMPO-1 in 2007-2008 * To evaluate the role of immune aging and inflammatory profile in the occurrence of comorbidities in HIV-infected individuals over a 15-year period

The alterations that affect the innate and adaptive immune cell compartments in HIV-infected patients are reminiscent of the process of immune aging, characteristic of old age. These alterations, the presumed cause of which is the chronic systemic immune activation established in patients, contribute to the depletion of lymphoid resources which probably leads to the decline of immune competence with the progression of HIV disease.

The comparison between HIV-1-infected patients and uninfected older adults goes beyond the mere appearance of immunosenescence and extends to the deterioration of a number of physiological functions linked to inflammation and to systemic aging.

By inducing persistent and lasting immune activation, HIV-1 infection is now considered a model of accelerated immunosenescence and systemic aging. During this process, the immune system quickly becomes exhausted, because the source of its exhaustion (i.e. HIV) cannot be eliminated.

To determine which factors may contribute to immunosenescence in HIV-1 infection, we propose an extensive immune and virological evaluation in patients who participated in a cross-sectional assessment of immune functions and TEMPO-1 viral reservoirs after 15 years of evolution in order to determine their immune and viral trajectories, to compare these trajectories with the major clinical events and the comorbidities occurring in them.

Inclusion: Previous participation to the TEMPO-1 study; 18 years of age or older; HIV-infected individuals and non-HIV infected control group; Be affiliated or beneficiary of a social security scheme; Have signed the consent form.

Exclusion: Subject under " sauvegarde de justice " (judicial protection due to temporarily and slightly diminished mental or physical faculties), or under legal guardianship.

ClinicalTrials.gov NCT06258122